CorMedix Inc.

CorMedix Inc. (collectively, with our wholly owned subsidiaries, referred to herein as we, us, our or the Company ) is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Our primary focus has been commercializing DefenCath (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis setting. The name DefenCath is the U.S. proprietary name approved by the U.S. Food and Drug Administration ( FDA ). On August 29, 2025, the Company acquired Melinta Therapeutics, LLC, a Delaware limited liability company ( Melinta ), which expanded the Company’s team, commercial platform and increased the commercial portfolio with six marketed, hospital- and clinic-focused infectious disease products, comprised of REZZAYO (rezafungin for injection), MINOCIN (minocycline) for Injection ( MINOCIN IV ), VABOMERE (meropenem and vaborbactam), KIMYRSA (oritavancin), ORBACTIV (oritavancin), and BAXDELA (delafloxacin), as well as an additional well-established cardiovascular product, TOPROL-XL (metoprolol succinate) (together, the Melinta Portfolio, and, together with DefenCath, our Products ). The Melinta Portfolio supports a multi-channel strategy of delivering anti-infectives for serious gram-positive, gram-negative and fungal infections within hospitals and the hospital ecosystem, including emergency departments, outpatient clinics and home infusion care, and provides synergy opportunities to drive growth for DefenCath.